RE-BVS – Piemonte Repository

Sfoglia per AUTORE
COGNETTI F
Collezione ASL Cuneo 2

Items : 4

Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. in Expert review of clinical pharmacology / Expert Rev Clin Pharmacol. 2021 Feb;14(2):261-268. doi: 10.1080/17512433.2021.1879639. Epub 2021 Jan

2021
ASL Cuneo 2

Procopio G; de Braud FG; Cappelletti V; Guadalupi V; Sepe P; Claps M; Donini M; Ortega C; Atzori F; Morelli F; Bearz A; Miceli R; Chiuri VE; Mosca A; Milella M; Mennitto A; Verzoni E; Cognetti F;

Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial in Annals of Oncology

2020
ASL Cuneo 2

Verzoni E; Claps M; Apollonio G; Guadalupi V; Montone R; Martinetti A; Sepe P; Mennitto A; Passalacqua R; Donini M; Atzori F; Ortega C; Morelli F; Bearz A; Chiuri VE; Mosca A; Milella M; Miceli R; Cognetti F; Procopio G;

Effect of gender on the outcome of patients receiing niolumab for metastatic renal cancer: Results from a large study population in Journal of Clinical Oncology

2019
ASL Cuneo 2

Procopio G; Di Cosimo S; De Giorgi U; Cartenì G; Cortesi E; Caserta C; Sabbatini R; Bearz A; Buti S; Pignata S; Berruti A; Ruggeri E; Bengala C; Livi L; Fagnani D; Bonetti A; Mitterer M; Ortega C; Cognetti F; Di Nicola MA;

A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial in Journal of Clinical Oncology

2018
ASL Cuneo 2

Procopio G; Cognetti F; Miceli R; Milella M; Mosca A; Chiuri VE; Bearz A; Morelli F; Ortega C; Atzori F; Donini M; Ratta R; Martinetti A; Montone R; De Braud FG; Cappelletti V; Verzoni E;